var data={"title":"Argatroban: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Argatroban: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5664?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=argatroban-patient-drug-information\" class=\"drug drug_patient\">see &quot;Argatroban: Patient drug information&quot;</a> and <a href=\"topic.htm?path=argatroban-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Argatroban: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136565\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Direct Thrombin Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136547\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin-induced thrombocytopenia (HIT):</b> Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial dose:</i> 2 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Critically-ill patients with normal hepatic function have become excessively anticoagulated with FDA-approved or lower starting doses of argatroban. Doses between 0.15 to 1.3 mcg/kg/minute were required to maintain aPTTs in the target range (Reichert 2003). In a prospective observational study of critically-ill patients with multiple organ dysfunction (MODS) and suspected or proven HIT, an initial infusion dose of 0.2 mcg/kg/minute was found to be sufficient and safe in this population (Beiderlinden 2007). Consider reducing starting dose to 0.2 mcg/kg/minute in critically-ill patients with MODS defined as a minimum number of two organ failures. Another report of a cardiac patient with anasarca secondary to acute renal failure had a reduction in argatroban clearance similar to patients with hepatic dysfunction. Reduced clearance may have been due to reduced liver perfusion (de Denus 2003). The American College of Chest Physicians has recommended an initial infusion rate of 0.5 to 1.2 mcg/kg/minute for patients with heart failure, MODS, severe anasarca, or postcardiac surgery (Linkins 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> Pharmacokinetics and pharmacodynamics have not been evaluated prospectively in obese patients; however, retrospective data suggest using actual body weight to dose and that adjustment of initial dose is unnecessary in obesity (BMI up to 51 kg/m<sup>2</sup>) (Rice 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose:</i> Patient may not be at steady-state but measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; dosage should not exceed 10 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion to oral anticoagulant:</i> Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients receiving &le;2 mcg/kg/minute of argatroban: Argatroban therapy can be stopped when the INR is &gt;4 on combined warfarin and argatroban therapy; repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients receiving &gt;2 mcg/kg/minute of argatroban: Reduce dose of argatroban to 2 mcg/kg/minute; measure INR for argatroban and warfarin 4 to 6 hours after dose reduction; argatroban therapy can be stopped when the INR on warfarin and argatroban combined therapy is &gt;4. Repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The American College of Chest Physicians suggests monitoring chromogenic factor X assay when transitioning from argatroban to warfarin (Garcia 2012) or overlapping administration of warfarin for a minimum of 5 days until INR is within target range; recheck INR after anticoagulant effect of argatroban has dissipated (Guyatt 2012). Factor X levels &lt;45% have been associated with INR values &gt;2 after the effects of argatroban have been eliminated (Arpino 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prefilter administration for continuous renal replacement therapy (CRRT) in critically-ill patients with HIT (off-label use; Link 2009):</b> 0.1 to 1.5 mcg/kg/minute. <b>Note:</b> Loading dose of 100 mcg/kg was administered during clinical trial; however, this may be unnecessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Percutaneous coronary intervention (PCI):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> Begin infusion of 25 mcg/kg/minute and administer bolus dose of 350 mcg/kg (over 3 to 5 minutes). ACT should be checked 5 to 10 minutes after bolus infusion; proceed with procedure if ACT &gt;300 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> Pharmacokinetics and pharmacodynamics have not been evaluated prospectively in obese patients; however, retrospective data suggest using actual body weight to dose and that adjustment of initial dose is unnecessary in obesity (BMI up to 51 kg/m<sup>2</sup>) (Hursting 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Following initial bolus: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ACT &lt;300 seconds: Give an additional 150 mcg/kg bolus, and increase infusion rate to 30 mcg/kg/minute (recheck ACT in 5 to 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ACT &gt;450 seconds: Decrease infusion rate to 15 mcg/kg/minute (recheck ACT in 5 to 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once a therapeutic ACT (300 to 450 seconds) is achieved, infusion should be continued at this dose for the duration of the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If dissection, impending abrupt closure, thrombus formation during PCI, or inability to achieve ACT &gt;300 seconds:</i> An additional bolus of 150 mcg/kg, followed by an increase in infusion rate to 40 mcg/kg/minute may be administered (recheck ACT after each additional bolus or change in infusion rate).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Post-PCI anticoagulation, if required, may be achieved by continuing infusion at a reduced dose of 2 mcg/kg/minute, with close monitoring of aPTT; adjust infusion rate as needed. Recheck ACT after each additional bolus or change in infusion rate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6273425\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=argatroban-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Argatroban: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Heparin-induced thrombocytopenia (HIT)</b> (dosing based on limited data from critically-ill patients): Infants, Children, and Adolescents &le;16 years: Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Initial dose:</i> 0.75 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Maintenance dose:</i> Measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; dosage may be adjusted in increments of 0.1 to 0.25 mcg/kg/minute. <b>Note:</b> Frequent dosage adjustments may be required to maintain desired anticoagulant activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Conversion to oral anticoagulant:</i> Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose. Once combined INR on warfarin and argatroban is &gt;4, stop argatroban. Repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained. Another option is to use factor X levels to monitor the effect of warfarin anticoagulation. When factor X level is &lt;0.3, warfarin is considered therapeutic and at which time argatroban can be discontinued (Alsoufi 2004, Boshkov 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136548\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136549\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to severe impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: Dialyzable, ~20% removed over 4 hours during hemodialysis (NCS/SCCM [Frontera 2016]); removal during hemodialysis and continuous venovenous hemofiltration did not alter clinical efficacy when used for anticoagulation in renal replacement therapy (Tang 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136550\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Heparin-induced thrombocytopenia (HIT):</i> Moderate to severe hepatic impairment (Child-Pugh class B and C): Continuous IV infusion: Initial: 0.5 mcg/kg/minute; monitor aPTT closely and adjust dose as necessary. However, patients with severe hepatic impairment (Child-Pugh class C) may require further reduction of the initial dose. One case report describes a dose of 0.05 mcg/kg/minute required to maintain a stable, therapeutic aPTT in a patient with severe hepatic impairment (Yarbrough 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Percutaneous coronary intervention (PCI):</i> Avoid use in patients with clinically significant hepatic impairment or elevations of ALT/AST &ge;3 times ULN (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents &le;16 years of age: Continuous IV infusion: Initial: 0.2 mcg/kg/minute; measure aPTT after 2 hours; adjust dose in increments of &le;0.05 mcg/kg/minute until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330502\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136522\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/125 mL (125 mL); 250 mg/250 mL (250 mL); 250 mg/2.5 mL (2.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/50 mL (50 mL); 250 mg/2.5 mL (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136507\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136524\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: The 2.5 mL (100 mg/mL) <b>concentrated</b> vial <b>must be diluted to 1 mg/mL</b> prior to administration. The premixed 50 mL or 125 mL vials and 250 mL bag (1 mg/mL) require no further dilution. The premixed 1 mg/mL vial may be inverted for use with an infusion set. For HIT, administer by continuous IV infusion. For PCI, administer by IV infusion and bolus (over 3 to 5 minutes through a large bore IV line).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471317\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 250 mg in 250 mL (concentration: 1000 <b>mcg</b>/mL) in D<sub>5</sub>W or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471318\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 1000 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136523\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin-induced thrombocytopenia:</b> Prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention:</b> As an anticoagulant for percutaneous coronary intervention (PCI) in adults who have or are at risk of developing HIT.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721918\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Extracorporeal circuit patency of continuous renal replacement therapy (CRRT) in critically-ill patients with HIT (maintenance)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136573\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Argatroban may be confused with Aggrastat, Orgaran</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136513\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all anticoagulants, bleeding is the major adverse effect of argatroban. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (PCI related: &lt;1% to 15%), hypotension (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Genitourinary tract hemorrhage (including hematuria; major: &lt;1%; minor: 2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasodilation (1% to 10%), cardiac arrest (6%), bradycardia (5%), ventricular tachycardia (5%), myocardial infarction (PCI: 4%), angina pectoris (2%), coronary occlusion (2%), ischemic heart disease (2%), thrombosis (&lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5%), pain (5%), intracranial hemorrhage (1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatological reaction (bullous eruption, rash; 1% to &lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 7%), diarrhea (6%), vomiting (4% to 6%), abdominal pain (3% to 4%), gastrointestinal hemorrhage (major: &lt;1% to 3%; minor: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hematocrit (minor: &le;10%; major: &lt;1%), decreased hemoglobin (minor: &le;10%; major: &lt;1%; &ge;2g/dl), groin bleeding (5%), brachial bleeding (2%), minor hemorrhage (CABG related: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (PCI related: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (10%), cough (3% to 10%), hemoptysis (minor: &le;1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&lt;1% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% (Limited to important or life-threatening): Aortic valve stenosis, bleeding at injection site (or access site; minor),cerebrovascular disease, gastroesophageal reflux disease, hypersensitivity reaction, local hemorrhage (limb and below-the-knee stump), pulmonary edema, retroperitoneal bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136527\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to argatroban or any component of the formulation; major bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136511\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: The most common complication is bleeding and can occur at any site in the body. Use extreme caution in patients with hematologic conditions associated with increased bleeding (eg, congenital or acquired bleeding disorders, GI lesions); recent puncture of large vessels or organ biopsy; spinal anesthesia; immediately following lumbar puncture; recent cerebrovascular accident (CVA), stroke, intracerebral surgery, or other neuraxial procedure; severe hypertension; renal impairment; recent major surgery; recent major bleeding (intracranial, GI, intraocular, or pulmonary). Monitor for signs and symptoms of bleeding. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Airway, skin, and generalized hypersensitivity reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction is necessary; may require &gt;4 hours to achieve full reversal of anticoagulant effects. Avoid use during PCI in patients with clinically significant hepatic impairment or elevations of ALT/AST &ge;3 times ULN (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Critically-ill patients: Use with caution in critically-ill patients; reduced clearance may require dosage reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136560\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136515\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8765&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136531\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to argatroban in pregnancy is limited. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136532\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if argatroban is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136520\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor hemoglobin, hematocrit, signs and symptoms of bleeding. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">HIT: Obtain baseline aPTT prior to start of therapy. Patient may not be at steady-state but check aPTT 2 hours after start of therapy to adjust dose, keeping the steady-state aPTT 1.5 to 3 times the initial baseline value (not exceeding 100 seconds).</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">PCI: Monitor ACT before dosing, 5 to 10 minutes after bolus dosing, and after any change in infusion rate and at the end of the procedure. Additional ACT assessments should be made every 20 to 30 minutes during extended PCI procedures. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136510\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A direct, highly-selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136526\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 174 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Albumin: 20%; alpha<sub>1</sub>-acid glycoprotein: 34% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via hydroxylation and aromatization (major route). Metabolism via CYP3A4/5 (minor route) to four metabolites. Unchanged argatroban is the major plasma component. Plasma concentration of metabolite M1 is 0% to 20% of the parent drug and is three- to five-fold weaker.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 39 to 51 minutes; Hepatic impairment: 181 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Steady-state: 1 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~65%; 14% unchanged); urine (~22%; 16% unchanged); low quantities of metabolites M2-4 in urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients (seriously ill): 0.16 L/kg/hour; 50% lower than healthy adults </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients (seriously ill with elevated bilirubin due to hepatic impairment or cardiac complications; n=4): 0.03 L/kg/hour; 80% lower than pediatric patients with normal bilirubin </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adult: 0.31 L/kg/hour (5.1 mL/kg/minute); hepatic impairment: 1.9 mL/kg/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136530\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Argatroban in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/250 mL (250 mL): $953.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Argatroban Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL (50 mL): $272.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/2.5 mL (2.5 mL): $612.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539819\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arganova (NL);</li>\n      <li>Argata (AT);</li>\n      <li>Argatra (DE);</li>\n      <li>Da Bei (CN);</li>\n      <li>Exembol (GB);</li>\n      <li>Novastan (CN, DK, IT, JP, KR, NO, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. <i>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</i>. 2004;7:155-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/15283365/pubmed\" target=\"_blank\" id=\"15283365\">15283365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban injection [prescribing information]. Princeton, NJ: Sandoz Inc.; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban injection 2.5 mL [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban solution [prescribing information]. Princeton, NJ: Sandoz Inc.; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arpino PA, Demirjian Z, and Van Cott EM, &ldquo;Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(2):157-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/15767231/pubmed\" target=\"_blank\" id=\"15767231\">15767231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baghdasarian SB, Singh I, Militello MA, et al, &ldquo;Argatroban Dosage in Critically Ill Patients With HIT,&rdquo; <i>Blood </i> 2004, 104:1779 [abstract 1779 from 2004 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beiderlinden M, Treschan TA, Gorlinger K, et al, &ldquo;Argatroban Anticoagulation in Critically Ill Patients,&rdquo; <i>Ann Pharmacother</i>, 2007, 41(5):749-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/17440009/pubmed\" target=\"_blank\" id=\"17440009\">17440009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boshkov LK, Kirby A, Shen I, et al. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. <i>Ann Thorac Surg.</i> 2006;81(6):S2355-S2359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/16731103/pubmed\" target=\"_blank\" id=\"16731103\">16731103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE and White RH, &ldquo;Pharmacotherapy of Heparin-Induced Thrombocytopenia,&rdquo; <i>Expert Opin Pharmacother</i>, 2003, 4(6):919-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/12783589/pubmed\" target=\"_blank\" id=\"12783589\">12783589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(9):1237-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/12921506/pubmed\" target=\"_blank\" id=\"12921506\">12921506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Honisko ME, Fink JM, Militello MA, et al, &ldquo;Compatibility of Argatroban With Selected Cardiovascular Agents,&rdquo; <i>Am J Health Syst Pharm</i>, 2004, 61(22):2415-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/15581266/pubmed\" target=\"_blank\" id=\"15581266\">15581266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hursting NJ and Jang IK, &quot;Impact of Renal Function on Argatroban Therapy During Percutaneous Coronary Intervention,&quot; <i>J Thromb Thrombolysis</i>, 2010 29(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/19504050/pubmed\" target=\"_blank\" id=\"19504050\">19504050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine RL, Hursting MJ, and McCollum D, &quot;Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction,&quot; <i>Chest</i>, 2006, 129(5):1167-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/16685006/pubmed\" target=\"_blank\" id=\"16685006\">16685006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis BE, Matthai WH, Cohen M, et al, &ldquo;Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2002, 57(2):177-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/12357516/pubmed\" target=\"_blank\" id=\"12357516\">12357516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis BE, Wallis DE, Berkowitz SD, et al, &ldquo;Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia,&rdquo; <i>Circulation</i>, 2001, 103(14):1838-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/11294800/pubmed\" target=\"_blank\" id=\"11294800\">11294800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19050602\"></a>Link A, Girndt M, Selejan S, et al, &ldquo;Argatroban for Anticoagulation in Continuous Renal Replacement Therapy,&rdquo; <i>Crit Care Med</i>, 2009, 37(1):105-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/19050602/pubmed\" target=\"_blank\" id=\"19050602\">19050602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linkins L, Dans AL, Moores LK, et al, &ldquo;Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e495-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/22315270/pubmed\" target=\"_blank\" id=\"22315270\">22315270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray PT, Reddy BV, Grossman EJ, et al, &ldquo;A Prospective Comparison of Three Argatroban Treatment Regimens During Hemodialysis in End-Stage Renal Disease,&rdquo; <i>Kidney Int</i>, 2004, 66(6):2446-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/15569338/pubmed\" target=\"_blank\" id=\"15569338\">15569338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reichert MG, MacGregor DA, Kincaid EH, et al, &ldquo; Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(5):652-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/12708939/pubmed\" target=\"_blank\" id=\"12708939\">12708939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rice L, Hursting MJ, Baillie GM, et al, &ldquo;Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,&rdquo; <i>J Clin Pharmacol</i>, 2007, 47(8):1028-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/17525167/pubmed\" target=\"_blank\" id=\"17525167\">17525167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang IY, Cox DS, Patel K, et al, &ldquo;Argatroban and Renal Replacement Therapy in Patients With Heparin-Induced Thrombocytopenia,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(2):231-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/15632219/pubmed\" target=\"_blank\" id=\"15632219\">15632219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yarbrough PM, Varedi A, Walker A, et al, &ldquo;Argatroban Dose Reductions for Suspected Heparin-Induced Thrombocytopenia Complicated by Child-Pugh Class C Liver Disease,&rdquo; <i>Ann Pharmacother</i>, 2012,46(11):e30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/23073302/pubmed\" target=\"_blank\" id=\"23073302\">23073302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. <i>Pediatr Blood Cancer</i>. 2011;56(7):1103-1109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-drug-information/abstract-text/21488155/pubmed\" target=\"_blank\" id=\"21488155\">21488155</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8765 Version 162.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136565\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F136547\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6273425\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F136548\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F136549\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F136550\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330502\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136522\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136507\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136524\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471317\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471318\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136523\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721918\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F136573\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136513\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136527\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136511\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F136560\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136515\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136531\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F136532\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F136520\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136510\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F136526\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F136530\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539819\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8765|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=argatroban-patient-drug-information\" class=\"drug drug_patient\">Argatroban: Patient drug information</a></li><li><a href=\"topic.htm?path=argatroban-pediatric-drug-information\" class=\"drug drug_pediatric\">Argatroban: Pediatric drug information</a></li></ul></div></div>","javascript":null}